Quarterly report pursuant to Section 13 or 15(d)

Revenue - Narrative (Details)

v3.20.2
Revenue - Narrative (Details)
€ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 08, 2018
USD ($)
performance_obligation
license
research_program
swap_option
May 02, 2017
performance_obligation
May 02, 2017
USD ($)
performance_obligation
May 02, 2017
performance_obligation
research_program
May 02, 2017
performance_obligation
license
May 02, 2017
performance_obligation
May 02, 2017
protein
performance_obligation
May 02, 2017
lease_agreement
performance_obligation
Jan. 04, 2017
USD ($)
performance_obligation
license
extension_option
bispecific_therapeutic_program
product
preclinical_Milestone
Jan. 04, 2017
EUR (€)
performance_obligation
license
extension_option
bispecific_therapeutic_program
product
preclinical_Milestone
Jun. 30, 2020
USD ($)
Feb. 28, 2019
USD ($)
Feb. 28, 2019
EUR (€)
Dec. 31, 2018
USD ($)
preclinical_Milestone
Dec. 31, 2018
EUR (€)
preclinical_Milestone
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jan. 01, 2019
USD ($)
May 02, 2017
collaboration_product
Disaggregation of Revenue [Line Items]                                          
Deferred revenues, current portion                     $ 7,912,000         $ 7,912,000   $ 7,912,000 $ 11,256,000    
Deferred revenue, net of current portion                     37,845,000         37,845,000   37,845,000 $ 47,258,000    
Revenue recognized from contract with customer                               3,700,000   13,800,000      
Additions to deferred revenue                               0   1,600,000      
Number of separate performance obligations (in performance obligations) | performance_obligation                 1 1                      
Number of technology licenses (in licenses) | lease_agreement               5                          
Seattle Genetics                                          
Disaggregation of Revenue [Line Items]                                          
Number of performance obligations (in performance obligations) | performance_obligation 3                                        
Remaining performance obligation                     19,800,000         19,800,000   19,800,000      
Deferred revenues, current portion                     1,400,000         1,400,000   1,400,000      
Deferred revenue, net of current portion                     15,200,000         15,200,000   15,200,000      
AstraZeneca                                          
Disaggregation of Revenue [Line Items]                                          
Remaining performance obligation                     23,200,000         23,200,000   23,200,000      
Deferred revenues, current portion                     1,100,000         1,100,000   1,100,000      
Deferred revenue, net of current portion                     17,200,000         17,200,000   17,200,000      
Research collaboration agreement term   5 years                                      
Les Laboratoires Servier and Institut de Recherches Internationales Servier                                          
Disaggregation of Revenue [Line Items]                                          
Number of performance obligations (in performance obligations) | performance_obligation                 10 10                      
Remaining performance obligation                     10,900,000         10,900,000   10,900,000      
Number of novel proteins (in proteins) | bispecific_therapeutic_program                 1 1                      
Deferred revenues, current portion                     5,500,000         5,500,000   5,500,000      
Deferred revenue, net of current portion                     5,400,000         5,400,000   5,400,000      
Capitalized contract cost, net                     100,000         100,000   100,000      
Revenue recognized from contract with customer                                 $ 7,100,000        
Number of research programs (in research programs) | bispecific_therapeutic_program                 3 3                      
Amortization of capitalized contract costs                                   100,000      
Number of separate performance obligations (in performance obligations) | performance_obligation                 2 2                      
Les Laboratoires Servier and Institut de Recherches Internationales Servier | Research and Development Services                                          
Disaggregation of Revenue [Line Items]                                          
Research collaboration agreement term                 3 years 3 years                      
Number of preclinical milestones (in preclinical milestones) | preclinical_Milestone                 2 2       1 1            
License and Collaboration Agreement | Seattle Genetics                                          
Disaggregation of Revenue [Line Items]                                          
Period after effective date agreements may be terminated 12 months                                        
Contract termination advance notice period 90 days                                        
Agreement termination advance notice period if marketing approval obtained 180 days                                        
Agreement termination notice period upon material breach by the Company 90 days                                        
Contract termination due to material breach, additional notice period if the breach is not susceptible 90 days                                        
Number of licenses (in licenses) | license 3                                        
Number of swap options (in swap options) | swap_option 2                                        
Number of performance obligations (in performance obligations) | performance_obligation 6                                        
Number of research programs (in research programs) | research_program 3                                        
License and Collaboration Agreement | AstraZeneca                                          
Disaggregation of Revenue [Line Items]                                          
Period after effective date agreements may be terminated   12 months                                      
Contract termination advance notice period   90 days                                      
Agreement termination advance notice period if marketing approval obtained   180 days                                      
Agreement termination notice period upon material breach by the Company   180 days                                      
Contract termination due to material breach, additional notice period if the breach is not susceptible   180 days                                      
Number of performance obligations (in performance obligations) | performance_obligation           16                              
Number of novel proteins (in proteins) | protein             4                            
Agreement termination notice period upon breach of payment obligations by the Company   30 days                                      
Period of license performance obligation   12 months                                      
License and Collaboration Agreement | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                          
Disaggregation of Revenue [Line Items]                                          
Number of licenses (in licenses) | license                 5 5                      
Number of performance obligations (in performance obligations) | performance_obligation                 4 4                      
Number of research programs (in research programs) | bispecific_therapeutic_program                 5 5                      
Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                          
Disaggregation of Revenue [Line Items]                                          
Period after effective date agreements may be terminated                 12 months 12 months                      
Contract termination advance notice period                 180 days 180 days                      
Revenue recognized from contract with customer                       $ 1,700,000 € 1.5 $ 600,000 € 0.5            
Number of collaboration products (in collaboration products) | product                 4 4                      
Other arrangement | Seattle Genetics                                          
Disaggregation of Revenue [Line Items]                                          
Number of research programs (in research programs) | research_program 2                                        
Platform technology license | Seattle Genetics                                          
Disaggregation of Revenue [Line Items]                                          
Number of performance obligations (in performance obligations) | performance_obligation 3                                        
Antibody target swap | Seattle Genetics                                          
Disaggregation of Revenue [Line Items]                                          
Number of performance obligations (in performance obligations) | performance_obligation 2                                        
Governance committee participation | Seattle Genetics                                          
Disaggregation of Revenue [Line Items]                                          
Number of performance obligations (in performance obligations) | performance_obligation 1                                        
Upfront Payment | Seattle Genetics                                          
Disaggregation of Revenue [Line Items]                                          
Research and development services $ 4,900,000                                        
Deferred revenue 1,200,000,000                                        
Upfront Payment | Seattle Genetics | License fees                                          
Disaggregation of Revenue [Line Items]                                          
Revenue $ 30,000,000.0                                        
Upfront Payment | AstraZeneca                                          
Disaggregation of Revenue [Line Items]                                          
Allocable arrangement consideration     $ 45,000,000.0                                    
Upfront Payment | Les Laboratoires Servier and Institut de Recherches Internationales Servier | License fees                                          
Disaggregation of Revenue [Line Items]                                          
Revenue                 $ 32,000,000.0 € 30.0                      
Additional other research services | AstraZeneca                                          
Disaggregation of Revenue [Line Items]                                          
Allocable arrangement consideration     4,700,000                                    
Estimated Development and Manufacturing Services | Upfront Payment | AstraZeneca                                          
Disaggregation of Revenue [Line Items]                                          
Allocable arrangement consideration     14,200,000                                    
Milestone Payments | Upfront Payment | Seattle Genetics                                          
Disaggregation of Revenue [Line Items]                                          
Revenue recognized from contract with customer                     4,200,000         4,200,000          
Allocable arrangement consideration                               5,000,000.0          
Milestone Payments | Upfront Payment | AstraZeneca                                          
Disaggregation of Revenue [Line Items]                                          
Allocable arrangement consideration     12,500,000                                    
Estimated Phase 2a Services | Upfront Payment | AstraZeneca                                          
Disaggregation of Revenue [Line Items]                                          
Allocable arrangement consideration     $ 4,700,000                                    
Agreement extension options (in extension options) | Les Laboratoires Servier and Institut de Recherches Internationales Servier | Research and Development Services                                          
Disaggregation of Revenue [Line Items]                                          
Research collaboration agreement term                 1 year 1 year                      
Number of agreement extension options (in extension options) | extension_option                 2 2                      
Minimum | License and Collaboration Agreement | AstraZeneca                                          
Disaggregation of Revenue [Line Items]                                          
Number of collaboration products (in collaboration products) | collaboration_product                                         2
Minimum | Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                          
Disaggregation of Revenue [Line Items]                                          
Agreement termination notice period upon material breach by the Company                 90 days 90 days                      
Maximum | License and Collaboration Agreement | AstraZeneca                                          
Disaggregation of Revenue [Line Items]                                          
Number of research programs (in research programs) | research_program       2                                  
Number of collaboration products (in collaboration products)   4 4 4 4 4 4 4                         4
Number of research licenses (in licenses)         4     4                          
Maximum | Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                          
Disaggregation of Revenue [Line Items]                                          
Agreement termination notice period upon material breach by the Company                 120 days 120 days                      
Accounting Standards Update 2014-09 | AstraZeneca                                          
Disaggregation of Revenue [Line Items]                                          
Capitalized contract cost, net                     $ 600,000         $ 600,000   $ 600,000   $ 1,600,000  
Capitalized contract cost in accordance with ASC 340                                       1,100,000  
Accounting Standards Update 2014-09 | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                          
Disaggregation of Revenue [Line Items]                                          
Capitalized contract cost, net                                       $ 500,000